Crisaborole Efficacious and Well Tolerated in Patients With Mild to Moderate AD

Crisaborole is well tolerated and effective in patients with mild to moderate atopic dermatitis (AD) and other comorbidities, according to a recent study published in Allergy and Asthma Proceedings.

Researchers performed a post hoc analysis of the phase 3 studies CrisADe, CORE 1, and CORE 2 to assess the efficacy and safety of crisaborole vs vehicle in 1522 patients aged 2 years or older with mild to moderate AD and a medical history of asthma, allergic rhinitis, or food allergies. Efficacy was determined in patients who achieved Investigator Static Global Assessment (ISGA) success at day 29, ISGA clear or almost clear at day 29, and improvement in the Severity of Pruritus Scale score at week 4.

Patients treated with crisaborole achieved ISGA clear or almost clear at day 29 in a greater proportion than other subgroups. Overall, treatment-related emergent adverse events (TREAEs) were mild to moderate in severity, and application-site pain was the most common TREAE.

“Crisaborole was efficacious and well tolerated in patients with mild to moderate AD and other atopic comorbidities, which suggested that crisaborole should be considered for the management of AD in this population,” concluded the study authors.

Reference

Spergel JM, Blaiss MS, Lio P, et al. Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities. Allergy Asthma Proc. 2021;42(5):425-431. doi:10.2500/aap.2021.42.210064